Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2021-10-29. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The company is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción AURA?
El precio actual de AURA es de $5.67, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Aura Biosciences Inc?
Aura Biosciences Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Aura Biosciences Inc?
La capitalización bursátil actual de Aura Biosciences Inc es $352.2M
¿Es Aura Biosciences Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para Aura Biosciences Inc, incluyendo 3 fuerte compra, 8 compra, 1 mantener, 0 venta, y 3 fuerte venta